Clinical Trial

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Study acronym: MEND-HD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-30; most recent amendment 2026-01-25.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT07010705
Lead Sponsor University of Rochester
Collaborators: Food and Drug Administration (FDA)
Conditions Huntington Disease, Healthy
Enrollment 100 participants
Start Date 2025-06-20
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-27